Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
Why Is Tradr 2X Long TEM Daily ETF (TEMT) Stock Down -15.06% Today?

Why Is Tradr 2X Long TEM Daily ETF (TEMT) Stock Down -15.06% Today?

Key Takeaways

  • TEMT shares fell 15.06% to $22.45 in Monday trading, a decline of $3.98 from Friday's close of $26.43.
  • The primary driver is a roughly 7.3% intraday drop in underlying Tempus AI shares, which the fund is designed to track at two times daily leverage.
  • No fund-specific or company-specific disclosure was released; the weakness reflects a risk-off rotation out of high-beta AI and growth names, firming Treasury yields and caution ahead of Nvidia's results.
  • A third consecutive down session for Tempus AI and profit-taking after the post-earnings run added pressure, extending Friday's 5.7% decline.
  • Trading activity was thin, with roughly 25,000 shares changing hands by early afternoon against a typical full-session pace well above 175,000.
  • News Significance Score: 18/100 - No fresh catalyst, and a move that is roughly 1.8x this fund's usual daily swing.
  • What traders are watching next: Nvidia's earnings, Treasury yields, the Personalis shareholder vote on Nov. 30, and whether Tempus AI can hold its recent support zone.
  • Deeper research is available on the Price Targets, Earnings and Forecast pages for this ticker.
  • Readers tracking systematic strategies can review the strongest current performers on Trending AI Robots.

Opening Summary

Tradr 2X Long TEMT Daily ETF (TEMT) is a small, single-stock leveraged fund that seeks twice the daily percentage performance of Tempus AI (TEM) common stock, the Chicago-based precision-medicine and healthcare data company. The ETF moves only as fast as its underlying, and on Monday that underlying moved sharply lower. TEMT traded at $22.45, down 15.06% from Friday's $26.43 close, a decline of $3.98. The move was confirmed as a decline, not a bounce. Markets cited no new fund or issuer news; the driver was the underlying stock's slide of roughly 7.3%, doubled by the fund's daily leverage and compounded by the fixed-cost drag built into daily-reset leveraged products.

Leverage Mechanics Amplified the Underlying Slide

TEMT does not pick its own direction. Its mandate is a 200% daily exposure to Tempus AI, reset each session, which means a 7% move in the underlying translates into roughly a 14% move in the fund before fees and compounding effects. Monday's session delivered exactly that math: Tempus AI fell to about $66.39 from $71.60, and the ETF's 15.06% decline tracked closely with the doubled daily return. Because the fund resets daily, volatile stretches in the underlying erode net asset value faster than a simple two-times multiple would suggest, and the vehicle's net assets of roughly $35 million make it sensitive to order flow.

Risk-Off Rotation Hit High-Beta AI Names

The broader catalyst was a rotation away from speculative, high-multiple AI and genomics names. Tempus AI carries a beta of about 3.6, making it one of the more rate-sensitive growth equities in healthcare, and Monday's tape featured firming Treasury yields, pressure across AI-adjacent equities and caution ahead of Nvidia's results on Tuesday. Peer diagnostics and genomics names traded broadly lower as well, so the move was sector-wide rather than idiosyncratic. Market participants also pointed to the possibility that investors are liquidating existing technology positions to fund participation in anticipated AI-related new issues, a dynamic that disproportionately hits crowded, high-beta holdings.

Post-Earnings Profit-Taking Extended a Three-Session Slide

Tempus AI's third-quarter report on Nov. 2 was strong: revenue of $411.5 million rose 23% year over year, adjusted EBITDA reached $25.6 million, and management raised its 2026 revenue outlook to $1.60 billion to $1.605 billion. The stock rallied hard on those numbers, and Jefferies subsequently lifted its rating to Hold from Underperform with a $70 price target. Monday's action was the third consecutive lower session and followed a 5.7% drop on Friday, consistent with profit-taking in a stock still sitting well below its September high. The company also continues to await shareholder approval of its pending Personalis acquisition, with a vote scheduled for Nov. 30.

Market Context and Trading Activity

Volume was not elevated. Roughly 25,000 TEMT shares traded by early afternoon against a typical full-session average in the 175,000 to 270,000 range, indicating that the decline was driven by a thin order book rather than heavy institutional distribution. The move was aligned with the underlying and with broader weakness in genomics and diagnostics peers, while the major indices themselves were far more contained, underlining that this was a high-beta, single-name event rather than a market-wide selloff. Technically, the fund broke below its 20-day moving average and lost the $24 area that had acted as support late last week, with the next reference points the mid-November low near $22.12 and, above the market, the $26 to $27 zone.

News Significance Score

The score runs from 0, meaning no meaningful news and a price move that is normal for the instrument, to 100, meaning transformative news and an extreme, rare move. This event scores 18 out of 100. The verified news was weak: there was no issuer disclosure, no filing and no analyst action specific to the fund, only a sector- and macro-driven decline in the underlying stock that was already in progress. The price move was also unremarkable by this instrument's standards. At 15.06%, it was about 1.8 times the typical 8.4% absolute daily move, and 11 of the last 60 sessions produced moves of equal or larger size. With both components weak, the result is a low score.

What Comes Next for TEMT

Attention now shifts to the underlying company's news flow. Tempus AI has no scheduled earnings release before its fourth-quarter report, but the Nov. 30 Personalis shareholder vote is a defined event that could move the stock, and any update on the Bristol Myers Squibb and Moderna/Merck collaborations would matter. On the macro side, Nvidia's results on Tuesday and the path of Treasury yields will shape appetite for high-beta AI exposure. Analyst sentiment remains constructive, with a consensus leaning toward Buy, though the Jefferies target near $70 sits close to the current price. Risks include further multiple compression in unprofitable growth names, integration risk around the pending acquisition, and the structural drag that daily rebalancing imposes on leveraged funds during choppy markets.

Trending AI Robots

Tickeron maintains hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. The bots differ widely by strategy, timeframe, performance metrics and the symbols they trade, so the page offers a practical way to compare approaches side by side. For traders navigating a fast-moving, leveraged instrument like this one, reviewing which strategies are currently working can sharpen execution and risk discipline. Explore the page to see which bots are leading right now.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TEMT

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


TEMT in upward trend: 10-day moving average crossed above 50-day moving average on November 06, 2026

The 10-day moving average for TEMT crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 4 of 4 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +41.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where TEMT advanced for three days, in 76 of 80 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 15 of 16 cases where TEMT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TEMT as a result. In 22 of 22 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for TEMT turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 12 similar instances when the indicator turned negative. In 12 of the 12 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

TEMT moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TEMT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

TEMT broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for TEMT entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Industry description

The investment seeks daily investment results, before fees and expenses, that correspond to two times (200%) the daily performance of the common shares of TEM. Under normal market circumstances, the fund will maintain at least 80% exposure to financial instruments that provide two times leveraged exposure to the daily performance of TEM. The Advisor attempts to consistently apply leverage to increase the fund’s exposure to 200% of TEM, and expects to rebalance the fund’s holdings daily to maintain such exposure. The fund is non-diversified.
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
ACHR fell -7.44% in Monday's regular session, sliding from Friday's $4.03 close to $3.73 shortly after 10 a.m. ET — a third consecutive daily decline that pushed shares back toward their November 5 low. No verified news or fundamental catalyst found for today's leg lower; the selling extends the de-rating that followed Q3 results — revenue of just $5.1 million, a net loss widening 111% to $274.6 million, and price-target cuts from Cantor Fitzgerald, Needham and Canaccord.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
Dell Technologies (DELL) fell roughly 23.7% over the last 30 days, sliding from a closing price of $451.71 on October 16, 2026, to $344.53 on November 13, 2026. The decline accelerated after the U.S. midterm elections, when investor concerns about potential AI and data-center regulation triggered a sharp sell-off across AI hardware names.
LITE is the Nasdaq-listed ticker for Lumentum Holdings Inc., a global manufacturer of optical and photonic products used in data centers, AI infrastructure, and telecommunications networks. The company was spun off from JDS Uniphase and incorporated in 2015, with headquarters in San Jose, California.